Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.12 USD
Change Today 0.00 / 0.00%
Volume 111.1K
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

celladon corp (CLDN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $28.25
52 Week Low
08/24/15 - $1.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLADON CORP (CLDN)

Related News

No related news articles were found.

celladon corp (CLDN) Related Businessweek News

No Related Businessweek News Found

celladon corp (CLDN) Details

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treatment of cardiac ischemic damage; and compounds for the treatment of diabetes and neurodegenerative diseases. Celladon Corporation was founded in 2000 and is headquartered in San Diego, California.

23 Employees
Last Reported Date: 08/11/15
Founded in 2000

celladon corp (CLDN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $189.7K
Vice President, General Counsel and Secretary
Total Annual Compensation: $233.8K
Vice President of Corporate Development & Inv...
Total Annual Compensation: $190.4K
Vice President of Corporate Operations
Total Annual Compensation: $216.3K
Vice President of Clinical Operations
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2014.

celladon corp (CLDN) Key Developments

Pomerantz LLP Announces Class Action Lawsuit Against Celladon Corporation

Pomerantz LLP announced that a class action lawsuit has been filed against Celladon Corporation and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 inclusive (class period).  This class action seeks to recover damages against defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. If users are a shareholder who purchased Celladon securities during the class period, the user will have until August 31, 2015 to ask the Court to appoint user as Lead Plaintiff for the class. The complaint alleged that throughout the class period, defendants made false and misleading statements and/or failed to disclose adverse information regarding the prospects for MYDICAR, the company's first most promising investigational drug for heart failure patients.

Celladon Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celladon Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $16,075,000 compared to $7,005,000 a year ago. Consolidated net loss was $16,525,000 compared to $6,992,000 a year ago. For the six months period, the company reported loss from operations of $32,372,000 compared to $13,929,000 a year ago. Consolidated net loss was $33,271,000 compared to $14,154,000 a year ago.

Celladon Appoints Wedbush As Financial Advisor For Sale Process

Celladon Corporation (NasdaqGM:CLDN) announced the engagement of Wedbush Securities Inc. as its exclusive financial advisor and a strategic plan pursuant to which it immediately commenced a process to seek a merger or sale.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLDN:US $1.12 USD 0.00

CLDN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLDN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLDN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLADON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at